Comparison of clinical efficacy of nedaplatin and cisplatin combined with docetaxel in the treatment of cervical cancer
10.3760/cma.j.issn.1008-6706.2017.16.007
- VernacularTitle:奈达铂与顺铂分别联合多西他赛治疗宫颈癌的临床疗效比较
- Author:
Lili GAO
;
Xiaoming WANG
;
Junhui CHEN
;
Jinfang ZHONG
;
Xinhui JIA
- Keywords:
Cisplatin;
Nedaplatin;
Docetaxel;
Uterine cervical neoplasms;
Antineoplastic combined chemotherapy protocols
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(16):2427-2430
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the clinical efficacy of nedaplatin and cisplatin combined with docetaxel in the treatment of cervical cancer.Methods 80 patients with cervical cancer were selected as the research subjects.According to different chemotherapy regimens,they were divided into observation group(40 cases)and control group(40 cases).The observation group adopted nedaplatin combined with docetaxel chemotherapy regimen,while the control group used cisplatin plus docetaxel chemotherapy regimens.The clinical curative effect,adverse reaction of chemotherapy,hospitalization related indicators,etc were compared between the two groups.Results The total effective rate of the observation group was 85.0%,which of the control group was 77.5%,the difference was not statistically significant(x2=0.739,P=0.739).The incidence rate of gastrointestinal reaction(Ⅰ-Ⅳ)in the observation group was 25.0%,which was lower than 82.5% in the control group(x2=26.560,P=0.000).The incidence rate of renal toxicity(grade Ⅰ-Ⅱ)of the observation group was 2.5%,which was lower than 17.5% of the control group(x2=5.000,P=0.025).The length of hospital stay of the observation group was(2.93 ±0.39)days,which was shorter than(4.97 ±0.81)days of the control group(t=14.352,P=0.000).The incidence rate of bone marrow inhibition(grade Ⅰ-Ⅱ)of the observation group was 43.0%,which was significantly higher than 25.0% of the control group(x2=4.381,P=0.036).1 year overall survival(OS),no local recurrence rate(LRF)and no distant metastasis survival rate(DMF)between the two groups had no statistically significant differences(all P>0.05).Conclusion Efficacy of nedaplatin or cisplatin combined with docetaxel in adjuvant chemotherapy of cervical cancer has similar prognosis,nedaplatin has less toxicity,and can shorten the time of hospitalization,patients are more likely to accept,it is worthy of clinical promotion.
